2023 World Conference on Lung Cancer (Posters)-EP10.01. Chemotherapy Outcomes in EGFR-TKI Resistant Patients: A Comparison of Common and Uncommon EGFR Mutation Subtypes

EP10.01. Chemotherapy Outcomes in EGFR-TKI Resistant Patients: A Comparison of Common and Uncommon EGFR Mutation Subtypes - PDF(Slides)

Back to course

Pdf Summary

A retrospective study compared the treatment outcomes of patients with non-small cell lung cancer (NSCLC) who had common and uncommon epidermal growth factor receptor (EGFR) mutations. The study found that patients with uncommon EGFR mutations had poorer responses to chemotherapy and shorter survival compared to those with common EGFR mutations. The study also identified several prognostic factors for progression-free survival (PFS) and overall survival (OS), including age, performance score, and EGFR mutation type. The findings suggest the need for new treatment strategies for patients with uncommon EGFR mutations.

Asset Subtitle

Jeng Shiuan Tsai

Meta Tag

Speaker Jeng Shiuan Tsai

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

retrospective study

treatment outcomes

NSCLC

EGFR mutations

chemotherapy

survival

prognostic factors

progression-free survival

overall survival

new treatment strategies